Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciclesonide + fluticasone propionate + salmeterol
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Inhalation, Intranasal
01
Overview
This is a combination therapy consisting of ciclesonide (an inhaled corticosteroid), fluticasone propionate (an inhaled corticosteroid), and salmeterol (a long-acting beta2-adrenergic agonist). Clinical studies have investigated the administration of ciclesonide alongside the fixed combination of fluticasone propionate/salmeterol, particularly examining their effects on cortisol suppression in patients with allergic rhinitis and asthma. The combination has been studied for its efficacy in managing asthma and allergic rhinitis.
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ciclesonide + fluticasone propionate + salmeterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciclesonide + fluticasone propionate + salmeterol.